Read article – An article remembering the life and career of Elmer Pfefferkorn, a beloved professor at the Geisel School of Medicine for 40-plus years and taught microbiology and virology and conducted groundbreaking, National Institutes of Health-supported research on parasites.

Read article – Ellen Flaherty, assistant professor of medicine, community and family medicine, and of The Dartmouth Institute for Health Policy and Clinical Practice, is quoted in an article that examines what to do about an aging relative who owns a weapon but may no longer be capable of using it responsibly.

Read article – Continued coverage of comments by Steven Woloshin, professor of medicine, community and family medicine, and of the Dartmouth Institute for Health Policy and Clinical Practice, in an article about a “disease awareness” campaign for a pill called Addyi from Sprout Pharmaceuticals, and how these types of campaigns trouble critics because of the attempts to define low sexual desire as a widespread disease that is treatable with a pill. “[Sprout is] definitely appropriating all that language, making it seem like a feminist issue,” says Woloshin. “This is an issue that involves women, but that doesn’t mean that taking this drug is something you should do because you’re a feminist.”

Read article – Ellen Meara, professor of The Dartmouth Institute for Health Policy and Clinical Practice and adjunct professor in economics, is quoted in an article about the issue of health care reform as the 2020 election approaches, and how Medicare for All is a proposal that has emerged as an early favorite. Many health economists are open to the idea of substantial reform, but “politically, it’s just not realistic,” says Meara.

Read article – Quotes Steven Woloshin, professor of medicine, community and family medicine, and of The Dartmouth Institute for Health Policy and Clinical Practice, in an article about a “disease awareness” campaign for a pill called Addyi from Sprout Pharmaceuticals, and how these types of campaigns trouble critics because of the attempts to define low sexual desire as a widespread disease that is treatable with a pill. “[Sprout is] definitely appropriating all that language, making it seem like a feminist issue,” says Woloshin. “This is an issue that involves women, but that doesn’t mean that taking this drug is something you should do because you’re a feminist.” (Picked up by KXLH.)

Read article – Cites a joint study from the Dartmouth Institute for Health Policy and Clinical Practice and the White River Junction VA Medical Center that found that VA medical facilities achieve healthcare outcomes that are consistently as good as, or even better than, private alternatives in 121 regional markets.

Read article – Quotes Adrienne Faerber, a lecturer at The Dartmouth Institute for Health Policy and Clinical Practice, in an article about how the Trump administration moved forward on Wednesday with its plan to lower prescription drug prices by requiring drugmakers to display the list price. “When you go to the car dealer and you see that sticker price and you can negotiate a better price that can fit your budget directly with the car dealership,” Faerber explains. But, she says, drug prices are negotiated through layers of middlemen: “So you don’t get to negotiate based on these prices like you would with a car.”

Read article – Highlights the Dartmouth Atlas of Health Care, a project led by John Wennberg, active emeritus professor of The Dartmouth Institute for Health Policy and Clinical Practice and of community and family medicine, in an article about New Zealand’s health care system.

Read article – Quotes Steven Woloshin, professor of medicine, community and family medicine, and of The Dartmouth Institute for Health Policy and Clinical Practice, about research he co-authored that found that using terms such as “breakthrough” and “promising” can inflate people’s beliefs about the effectiveness of a new drug.

Read article – Quotes Elijah Stommel, professor of neurology, about data presented by drugmaker Cytokinetics from the Phase II FORTITUDE-ALS study of reldesemtiv in ALS at the American Academy of Neurology’s annual meeting in Philadelphia. Despite the trial not showing statistical significance on the primary or secondary efficacy endpoints in Phase II, the company views the data as supportive of reldesemtiv’s Phase III development. “Of course, the company is interested in making money,” said Stommel, who was not involved with the study. “Remember when a large Phase III trial is done, it prevents those ALS patients from participating in another trial that might have more efficacy.”